FindTrial
Sign In

Prediction Models of Drug Sensitivity to Venetoclax and Exploration of Resistance Mechanisms in T-cell Acute Lymphoblastic Leukemia

Prediction Models of Drug Sensitivity to Venetoclax and Exploration of Resistance Mechanisms in T-cell Acute Lymphoblastic Leukemia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600124387
Enrollment
Unknown
Registered
2026-05-11
Start date
2026-05-11
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

t cell acute lymphoblastic leukemia

Interventions

The remission group after treatment with Venetoclax plus chemotherapy.:None

Sponsors

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 75 Years

Inclusion criteria

Inclusion criteria: No gender restriction, no ethnic restriction, aged between 15 and 75, all study subjects are patients with acute T-cell lymphoblastic leukemia/lymphoma.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
complete remission rate;—

Countries

China

Contacts

Public ContactMi Jianqing

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

mjq10597@rjh.com.cn+86 21 6437 0045

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026